DCM
MRTX

DAFNA Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

DAFNA Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-89,387
Closed -$5.25M – 86
2023
Q4 		$5.25M Sell
89,387
-3,500
-4% -$197K 1.26% 26
2023
Q3 		$4.05M Sell
92,887
-1,813
-2% -$64.7K 1.26% 26
2023
Q2 		$3.42M Buy
94,700
+21,100
+29% +$869K 0.94% 33
2023
Q1 		$2.74M Hold
73,600
– – 0.82% 35
2022
Q4 		$3.33M Buy
73,600
+2,000
+3% +$129K 0.94% 32
2022
Q3 		$5M Sell
71,600
-8,000
-10% -$592K 1.35% 25
2022
Q2 		$5.34M Buy
79,600
+36,900
+86% +$2.35M 1.46% 22
2022
Q1 		$3.51M Buy
+42,700
New +$4.37M 0.91% 31
2020
Q3 		– Sell
-21,893
Closed -$2.5M – 93
2020
Q2 		$2.5M Sell
21,893
-20,209
-48% -$1.96M 0.72% 38
2020
Q1 		$3.24M Buy
+42,102
New +$3.78M 1.35% 23

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

DAFNA Capital Management's MRTX Position: Q1 2024 in Review

DAFNA Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 89,387 shares — an estimated $5.25M sold.

DAFNA Capital Management first reported a position in MRTX in Q1 2020 and held it in 10 quarters. The position peaked at $5.34M in Q2 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • DAFNA Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • DAFNA Capital Management sold 89,387 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $5.25M.
  • DAFNA Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 10 quarters.
  • DAFNA Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $5.34M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.